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Abstract
The authors aimed to introduce a medical application for nonwoven fabric as spacers
in particle therapy. Particle therapy, exhibiting more focused effects on target tissues,
has emerged as a promising treatment modality. However, close proximity of tumor
tissue and adjacent organs makes delivery of curative doses to the tumor difficult
because severe radiation morbidities might occur. A method using surgically placed
GORE-TEX sheets as a spacer has been reported. Although this method provides for
separation of adjacent organs, the material is not resorbed. To overcome these
anatomical and therapeutic difficulties, and to deliver effective radiation doses to treat
upper abdominal tumors, we have developed a nonwoven fabric spacer composed of
bioabsorbable suture material. The absorbable polyglycolic acid (PGA) spacer had
water-equivalent, biocompatible, and thickness-retaining properties. Although
further evaluation is warranted in a clinical setting, the PGA spacer may be effective
to block particle beams and to separate normal tissues from the radiation field. These
findings suggest that the nonwoven-fabric PGA spacer might become a useful device
in particle therapy.
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1. Introduction
Two of the properties of nonwoven fabrics that have justified previous use in medical products
are economic viability in single-use scenarios and reliable performance [1]. The design and
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performance characteristics of these products—which come into close contact with the human
body—are driven by their end use, which determines the desired function and barrier,
absorption, and strength properties, and the fact that any chemical additives need to be
biocompatible. Nonwoven products remain the component of choice for providing appropri‐
ate protection because of their ability to create barriers due to either the structure of the
nonwoven material itself or an additional active coating for personal protective apparel.
Nonwoven materials are also beginning to play a role in extracorporeal devices, such as
artificial lungs, hearts, and kidneys, as well as in ligament repairs and other skeletal scaffolds,
yet these uses are still rare compared with their other uses [2].
Radiotherapy is one of the strategies used against several cancers, and X-ray or particle beams
are mainly used for cancer treatment. Particle therapy, exhibiting more focused effects on
target tissues, has emerged as a promising treatment modality. Several systematic reviews
associated with proton or carbon-ion beam therapy discuss the extensive use of particle
therapy to treat various malignant tumors, including chordoma, ocular melanoma, and
prostate cancer [3–5]. Several studies have indicated the efficacy of proton therapy for the
treatment of hepatocellular carcinoma or pancreatic cancer [6–9]. However, in certain cases, it
is difficult to deliver curative doses of radiation to treat upper abdominal tumors without
damaging adjacent radiosensitive organs, such as the duodenum, jejunum, and stomach. To
overcome these anatomical difficulties and to deliver effective radiation doses to treat upper
abdominal tumors, nonwoven fabric barriers have been applied as spacers to separate tumors
and adjacent organs [10, 11].
2. Medical application of nonwoven fabric spacers
Nonwoven fabric is a fabric-like material manufactured from long fibers bonded together by
chemical, mechanical, heat, or solvent treatment. The performance characteristics of nonwoven
fabrics vary according to the material components and the manufacturing process. A charac‐
teristic of nonwoven fabrics is not to have directionality for strength or growth. In addition,
specific features of nonwoven fabrics include “water absorbency,” “chemical resistance,”
“breathability,” “abrasion resistance,” and “flexibility.” These characteristics of nonwoven
fabrics support their use as surgical gowns and hats, masks, drapes, water-absorbing mats,
and machine covers. The GORE-TEX sheet is a waterproof, breathable fabric membrane and
has been widely used in permanent implants, including the artificial blood vessel, for many
years. The GORE-TEX sheet was the first nonwoven fabric to be applied as a spacer in the field
of particle therapy [10–12] (Figure 1). The use of this spacer allows the application of particle
therapy in cases in which particle therapy may result in severe incurable damage to adjacent
organs. However, although the GORE-TEX spacer is useful during the period of particle
therapy, it becomes a foreign body after the therapy [12]. Problems related to the ongoing
presence of the spacer may be avoided by removal during a second surgery, but repeated
operations might be a risk for the patient.
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3. Usefulness of nonwoven fabric spacers in the treatment of pancreatic
cancer
Despite recent progress in treatment options for pancreatic cancer, survival rates have failed
to show any significant improvement [13]. Among these modalities, resection is the only
curative treatment for pancreatic cancer, but only 10%–15% of patients have operable tumors
[14, 15]. The remaining patients cannot undergo resection because of local invasion or distant
metastasis at the time of diagnosis [16]. Local invasion is found in approximately 40% of
patients with pancreatic cancer at the time of presentation and most commonly includes the
superior mesenteric vessels or the celiac trunk [17].
Chemoradiotherapy with concurrent 5-fluorouracil was historically considered the standard
therapy for locally advanced pancreatic cancer [18]. Recently, successful results have been
reported with the use of a combination of gemcitabine and proton therapy to treat this type of
advanced pancreatic cancer. However, reductions of the irradiation doses and target fields
were necessary because approximately 10% of the patients subsequently developed Grade 3
or higher gastric ulcers several months after completing the therapy [9]. In such cases, surgical
placement of a spacer between the pancreas and the gastrointestinal tract might be an effective
option to reduce gastrointestinal toxicity and allow the continued use of high doses of
radiation.
Among pancreatic cancers in various regions, good candidates for spacer placement are
unresectable pancreatic body and tail cancers. Pancreatic head cancer is not amenable to this
treatment strategy because the pancreatic head cannot be separated from the duodenum.
The treatment strategy aims to keep the gastrointestinal tract away from the irradiation field
by spacer placement and to allow the application of proton-beam radiotherapy with curative
intent. The GORE-TEX sheets and the omentum are superimposed and applied as a spacer to
maintain a safety margin of approximately 10 mm from the gastrointestinal tract. The spacer
is finely fixed to the retroperitoneum, peritoneum, stomach, and surrounding tissues using
4-0 nylon to avoid hernia formation. The use of absorbable sutures for the fixation must be
avoided because it leads to migration of the spacer. In the treatment of pancreatic body and
tail cancers, target gastrointestinal tract components to be protected by spacer placement
include the stomach, duodenum, small, jejunum, and colon. Of note, the protection of the
duodenal bulb and horizontal part of the duodenum in the region of the Treitz ligament is of
particular importance. The spacer placement surgery is a first step to allow proton-beam
radiotherapy, and no part of the tumor is resected during this procedure.
Until the end of 2013, 8 patients with unresectable pancreatic body and tail cancers were treated
by spacer placement and particle therapy as phase I and phase II trials. One-year and 2-year
survival rates were 87.5% and 43.8%, respectively. These patients were free from complications
associated with the gastrointestinal tract.
We believe that surgical spacer placement can be used to maintain a safety margin around the
gastrointestinal tract. In consequence, full-dose particle-beam radiotherapy for pancreatic
body and tail cancers can be achieved without serious toxicities.
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Figure 1. A case of pancreatic body cancer in which a GORE-TEX spacer was placed before the application of proton-
beam therapy. The left panels show perisurgical images during the placement of the GORE-TEX spacer. The right pan‐
els show computed tomography images, including tumors, liver, adjacent organs, and the GORE-TEX spacer (arrows)
after the surgery.
4. Novel nonwoven fabric bioabsorbable spacer for particle radiotherapy
The purpose to produce a bioabsorbable nonwoven fabric spacer is to overcome problems
associated with nonabsorbable GORE-TEX spacer [19]. The nonabsorbable GORE-TEX spacer
might cause serious complications after the completion of particle therapy. On the other hand,
although previous investigators have reported usefulness of gel spacers for separation of
prostate and rectum [20, 21], those spacers are inappropriate for the upper abdomen, which
contains lots of free space. Therefore, at present, a nonwoven fabric bioabsorbable spacer is
necessary and appropriate for the separation of tumor and adjacent organs of upper abdomen
malignancies.
The process for producing the nonwoven fabric involves entangling threads in 3 dimensions
with a needle-punching process and other methods [22, 23]. Spacer placement during radio‐
therapy is a promising method designed to allow increased tumor dose while limiting
radiation exposure to adjacent organs. The spacer exhibits excellent properties related to
bioabsorbability, biocompatibility, thickness retention, and water equivalency according to
physical and animal experiments (Figure 2). The reason and the advantage for the use of PGA
to construct this nonwoven fabric spacer are that PGA is one of the most widely studied
polymers and has excellent mechanical properties and biological affinity [24, 25]. Historically,
PGA has played a central role in surgery since its development as the first synthetic absorbable
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suture material in 1962 [26]. The PGA is absorbed in 60–90 days after insertion in the body. It
is hydrolyzed without any phagocytosis, which results in a weaker immune response than
that of absorbable organic sutures [27]. The degradation of PGA generally involves random
hydrolysis of their ester bonds. Under physiologic conditions, PGA is also degraded by certain
enzymes, especially those with esterase activity [28, 29]. The attractiveness of PGA as a
biodegradable polymer in medical application is that its degradation product glycolic acid is
a natural metabolite [29]. The glycolic acid is nontoxic and can enter the tricarboxylic acid cycle,
after which it is excreted as water and carbon dioxide. Part of the glycolic acid is also excreted
in urine [26, 28].
As for PGA sutures, Chu et al. have reported a simple degradation mechanism via homoge‐
neous erosion [30–32]. The degradation process occurs in two stages, the first involves the
diffusion of water into the amorphous regions of the matrix and simple hydrolytic chain
scission of the ester groups. The second stage of degradation involves largely the crystalline
areas of the polymer, which becomes predominant when the majority of the amorphous
regions have been eroded. It is important to note that PGA nonwoven fabric spacer is com‐
prised of the PGA suture mainly with a 3-dimensional needle-punching process. Therefore,
the degradation mechanism of the content of the PGA spacer could be same as PGA sutures.
However, it is possible that because the volume of PGA polymers in the PGA spacer is quite
large, inflammatory biological responses might be different from that of relatively small
volume of PGA suture (Figure 3).
Figure 2. Macroscopic features of a novel nonwoven-fabric bioabsorbable spacer composed of surgical polyglycolic
acid (PGA) sutures in the rat abdomen. The left panels show images of formalin-fixed specimens showing the abdomi‐
nal wall, implanted PGA spacer, and adjacent intestines. The right panels show images of the same specimens stained
with hematoxylin and eosin (HE). These images indicate that the PGA spacer was absorbed gradually.
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Figure 3. Microscopic features of the PGA bioabsorbable spacer implanted in the rat abdomen. In the surface of the
PGA spacer, inflammatory response was observed. There were degraded PGA fibers, lymphocyte, and macrophage
observed in the surface. Interestingly, very few cell infiltrations were observed in the body of the PGA spacer
Although there is no clear definition of a bioabsorbable nonwoven fabric spacer reported, an
optimal bioabsorbable spacer must have thickness-retaining and water-equivalency properties
according to treatment duration [19]. In particle therapies, because treatment protocols take
2–7 weeks [5, 33], a spacer that maintains its thickness for the duration of or slightly longer
than the treatment period seems to be ideal. From our investigation, the percentage of thickness
retention of the PGA spacer varies according to the concentration of the PGA sutures. The PGA
spacer product with 0.2 g/cm3 of PGA sutures retains more than 90% thickness for 8 weeks.
Therefore, this PGA spacer could be applied in various protocols in particle therapy. The
bioabsorbable PGA spacer might become a useful device and expand indications for particle
therapy.
5. Future direction of medical application of bioabsorbable nonwoven
fabric spacers
Adhesions after surgery might lead to serious complications [34, 35]. In the pelvic and
abdominal sites, these complications might lead to small-bowel obstruction, infertility, chronic
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pelvic pain, and difficulty with further surgical access. Therefore, regarding spacer placement,
it is necessary to minimize adhesions between the spacer and surrounding organs. In our
preclinical study, the efficacy and the safety of a bioabsorbable spacer composed of PGA
sutures were investigated in several animal models [19]. The PGA nonwoven fabric spacer
exhibited excellent properties, no toxic effects in the animals, and negligible adhesion forma‐
tion. However, different conditions between experimental animals and clinical settings might
affect outcomes, and adhesion formation may be different in the presence of malignant tumors.
Therefore, if it is necessary to improve properties of the nonwoven fabric PGA spacer, next-
generation spacers are expected to avoid adhesion as far as possible. A promising method
might be to combine an anti-adhesion material with the PGA spacer. In our recent observation
using a healthy rat model, adhesion was significantly decreased, and no exceptional toxicity
risk was observed compared with the control group. In the future, less-invasive methods,
including endoscopic surgery, might be applied for implantation of the spacer.
6. Conclusion
The absorbable PGA spacer had water-equivalent, biocompatible, and thickness-retaining
properties. Although further evaluation is warranted in a clinical setting, the PGA spacer may
be effective to block particle beams and to separate normal tissues from the radiation field.
These findings suggest that the nonwoven fabric PGA spacer might become a useful device in
particle therapy.
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